CCCC Q2 2025 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$243M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M-46.2% YoY

Gross Profit

$6M100.0% margin

Operating Income

-$29M-441.0% margin

Net Income

-$26M-402.6% margin

EPS (Diluted)

$-0.37

QoQ Revenue Growth

-10.7%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$297M

Total Liabilities

$122M

Stockholders' Equity

$174M

Cash & Equivalents

$78M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$12M	-46.2%
Gross Profit	$6M	$10M	-35.1%
Operating Income	-$29M	-$21M	-32.9%
Net Income	-$26M	-$18M	-46.9%